DNDI-6174 / Eisai, DNDi - LARVOL DELTA

Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics. (PubMed, Inflammopharmacology) - "On the therapeutic side, the present article assesses the existing evidence base of combination regimens, host-directed approaches, and new oral pipeline of novel oral candidates, under clinical development by DNDi and partner institutions, such as LXE408, DNDI-6174, liposomal nanoformulations. Further, the article provides a survey of the topography of diagnostic instruments, including strong points and translational shortcomings of parasitological confirmation, molecular and serological. Together, this review highlights the necessity of combined, surveillance-based, and target-specific strategies in order to support and prolong the achieved progress in VL eradication."

Journal • Review • Infectious Disease • AQP1

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "DNDI-6174 was stable under various conditions, including under tissue homogenization conditions, in all biomatrices investigated. This method was successfully applied in a translational study using a murine cutaneous leishmaniasis skin infection model to assess the target site pharmacokinetics of DNDI-6174, supporting its development as clinical candidate."

Journal • PK/PD data • Preclinical • Dermatology • Infectious Disease

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc. (PubMed, Sci Transl Med) - "No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis."

Journal • Preclinical • Infectious Disease